Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2004-06-04
2010-10-26
Jiang, Shaojia Anna (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S262100, C514S359000, C514S365000, C514S562000, C514S706000, C536S046000
Reexamination Certificate
active
07820640
ABSTRACT:
In one aspect, the present invention provides otoprotectant compositions useful for ameliorating hearing loss. In some embodiments, the otoprotective compositions comprise at least one glutathione peroxidase mimic. In some embodiments, the otoprotective compositions comprise at least one glutathione peroxidase mimic and at least one otoprotectant selected from the group consisting of a xanthine oxidase inhibitor and a glutathione or glutathione precursor. In some embodiments, the otoprotective compositions comprise at least one glutathione peroxidase mimic, at least one xanthine oxidase inhibitor, at least one glutathione or glutathione precursor. In another aspect, the present invention provides methods for ameliorating hearing loss by administering to a subject an amount of an otoprotective composition that is effective to ameliorate hearing loss.
REFERENCES:
patent: 4352799 (1982-10-01), Renson
patent: 4774252 (1988-09-01), Welter
patent: 5385726 (1995-01-01), Baldew
patent: 5795909 (1998-08-01), Shashoua
patent: 6093743 (2000-07-01), Lai
patent: 6177434 (2001-01-01), Kopke et al.
patent: 6601580 (2003-08-01), Bloch
patent: 6815434 (2004-11-01), Kil
patent: 2003/0157191 (2003-08-01), Kil
patent: 2004/0220145 (2004-11-01), Kil
patent: 2005/0147978 (2005-07-01), Remacle
patent: 2006/0089313 (2006-04-01), Kil
patent: 3638124 (1988-05-01), None
patent: 198 56 210 (2000-04-01), None
patent: 1 609 479 (2005-12-01), None
patent: 92/02221 (1992-02-01), None
patent: 01/80832 (2001-11-01), None
patent: 03045334 (2003-06-01), None
patent: 2004/080486 (2004-09-01), None
Attanasio et al. (Acta otorhinolaryngologica Italica: organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale, (Feb. 1999) 19 (1), pp. 6-11 (Abstract Sent).
Kopke et al. (Hearing Research (2000), 149 (1-2), 138-146) (Abstract Sent).
Herrick et al. (Clinical and Experimental Rheumatology, (May-Jun. 2000) 18 (3) 349-56).(Abstract Sent).
Dawson et al. (Neuroscience Letters (Feb. 6, 1995) vol. 185, No. 1, pp. 65-69) (Abstract Sent).
Palmer et al. (Pediatric Research (Apr. 1990) vol. 27, No. 4 pt 1, pp. 332-336) (Abstract Sent).
Cuzzocrea et al. (British Journal of Pharmacology, (Jul. 2000) vol. 130, No. 6, pp. 1219-1226) (Absract Sent).
Sies (Free Radical Biology & Medicine (1993), 14(3), 313-23)(Abstract Sent).
Cotgreave, I.A., and P. Moldéus, “Lung Protection by Thiol-Containing Antioxidants,”Bull. Eur. Physiopathol. Respir.23:275-277, 1987.
Cotgreave, I.A., et al., “The Anti-Inflammatory Activity of Ebselen But Not Thiols in Experimental Alveolitis and Bronchiolitis,”Agents and Actions24(3-4):313-319, 1988.
Dehne, N., et al., “In Vitro Effects of Hydrogen Peroxide on the Cochlear Neurosensory Epithelium of the Guinea Pig,”Hearing Research143(1-2):162-170, 2000 (abstract only).
Ferrer, J.V., et al., “Allopurinol and N-Acetylcysteine Avoid 60% of Intestinal Necrosis in an Ischemia-Reperfusion Experimental Model,”Transplantation Proceedings30:2672, 1988.
Gustafson, D.L., and C.A. Pritsos, “Inhibition of Mitomycin C's Aerobic Toxicity by the Seleno-Organic Antioxidant PZ-51,”Cancer Chemother. Pharmacol.28:228-230, 1991.
McFadden, S.L., et al., “M40403, a Superoxide Dismutase Mimetic, Protects Cochlear Hair Cells From Gentamicin, But Not Cisplatin Toxicity,”Toxicology and Applied Pharmacology186:46-54, 2003.
Pritsos, C.A, et al., “PZ-51 (Ebselen) In Vivo Protection Against Adriamycin-Induced Mouse Cardiac and Hepatic Lipid Peroxidation and Toxicity,”Biochemical Pharmacology44(4):839-841, 1992.
Ren, X., et al., “A Novel Glutathione Peroxidase Mimic With Antioxidant Activity,”Archives of Biochemistry and Biophysics, 387(2):250-256, 2001.
Rybak, L.P., and S. Somani, “Ototoxicity: Amelioration by Protective Agents,”Annals of the New York Academy of Sciences884:143-151, 1999 (abstract only).
Rybak, L.P., et al., “Effect of Protective Agents Against Cisplatin Ototoxicity,”The American Journal of Otology21(4):513-520, 2000.
Seidman, M.D., et al., “The Protective Effects of Allopurinol and Superoxide Dismutase-Polyethylene Glycol on Ischemic and Reperfusion-Induced Cochlear Damage,”Otolaryngology—Head and Neck Surgery, 105(3):457-463, Sep. 1991.
Song, B.-B., and J. Schacht, “Variable Efficacy of Radical Scavengers and Iron Chelators to Attenuate Gentamicin Ototoxicity in Guinea Pig In Vivo,”Hearing Research 94(1-2):87-93, 1996 (abstract only).
Usui, M., et al., “Pathogenic Role of Oxidative Stress in Vascular Angiotensin-Converting Enzyme Activation in Long-Term Blockade of Nitric Oxide Synthesis in Rats,”Hypertension 34(4):546-551, 1999.
Vermeulen, N.P.E., et al., “Toxicity of Fotemustine in Rat Hepatocytes and Mechanism-Based Protection Against It,”Chemico-Biological Interactions 110:139-158, 1998.
Lopez-Gonzalez, M.A., et al., “Ototoxicity Caused by Cisplatin Is Ameliorated by Melatonin and Other Antioxidants,” Journal of Pineal Research 28:73-80, 2000.
Physicians Desk Reference, 51st ed., 1997, pp. 1194-1196.
“Cancer Multidrug Resistance,” Nature Biotechnology 18(Supplement):IT18-IT20, 2000, reprinted from Nature Biotechnology 17:94-95, 1999.
Baldew, G.S., et al., “The Influence of Ebselen on the Toxicity of Cisplatin in LLC-PK1 Cells,” Biochemical Pharmacology 44(2):382-387, Jul. 22, 1992.
Baldew, G.S., et al., Selective Reduction of cis-Diamminedichloroplatinum(II) Nephrotoxicity by Ebselen, Cancer Research 50:7031-7036, Nov. 1, 1990.
Coleman, J.K.M, et al., “Low Dose Methionine with N-Acetyl-L-Cysteine Reduces Noise-Induced Threshold Shift in the Chinchilla,” ARO Abstract No. 861 25:226, Jan. 15, 2002.
Coleman, J.K.M., et al., “Post-Noise Administration of Methionine Attenuates Noise-Induced Hearing Loss in the Chinchilla,” ARO Abstract No. 862 25:226, Jan. 15, 2002.
Curti, B.D., “Physical Barriers to Drug Delivery in Tumors,” Critical Reviews in Oncology/Hematology 14:29-39, 1993.
Doi, K, et al., “Radical Scavenger Edaravone Developed for Clinical Use Ameliorates Ischemia/Reperfusion Injury in Rat Kidney,” Kidney International 65: 1714-1723, 2004.
Duon, M., et al. “Antioxidant N-L-Acetylensteine (NAC) Can Protect Cochlea From Impulse Noise Trauma,” ARO Abstract No. 860 25:226, Jan. 15, 2002.
Ekborn, A., et al., “Intracochlear Administration of Thiourea Protect Against Cisplatin Induced Ototoxicity in the Guinea Pig,” ARO Abstract No. 854 25:224, Jan. 15, 2002.
Fischer, H., et al., “A Novel Biologically Active Selenoorganic Compound. VIII. Biotransformation of Ebselen,” Xenobiotica 18(12):1347-1359, Dec. 1988.
Gillette Cloven, N., et al., “Evaluation of D-Methionine as a Cytoprotectant in Cisplatin Treatment of an Animal Model for Ovarian Cancer,” Anticancer Research 20:4205-4209, Nov.-Dec. 2000.
Greenberg, B., et al., “Neoadjuvant Therapy for Advanced Head and Neck Cancer With Allopurinol-Modulated High Dose 5-Flourouracil and Cisplatin,” Cancer 59(11):1860-1865, Jun. 1, 1987.
Husain, K, et al., “Carboplatin-Induced Oxidative Stress in Rat Cochlea,” Hearing Research 158:14-22, 2001.
Iwasaka, K., et al., “Role of Hydrogen Peroxide in Cytotoxicity Induction by Ascorbates and Other Redox Compounds,” Anticancer Research 18:4333-4337, 1998.
Jain, R.K., “Barriers to Drug Delivery in Solid Tumors,” Scientific American 271(1):58-65, Jul. 1994.
Johnson, J.I., et al., “Relationships Between Drug Activity in NCI Preclinical In Vitro and In Vivo Models and Early Clinical Trials,” British Journal of Cancer 84(10):1424-1431, 2001.
Kalinec, G.M., et al., “Protective Role of L-Carnitine on the Ototoxic Effects of Cisplatin in Newborn Guinea Pigs,” ARO Abstract No. 855 25:225, Jan. 15, 2002.
Kern, D.H., “Heterogeneity of Drug Resistance in Human Breast and
Kil Jonathan
Lynch Eric D.
Christensen O'Connor Johnson & Kindness PLLC
Henry Michael C
Jiang Shaojia Anna
Sound Pharmaceuticals Incorporated
LandOfFree
Methods for treating hearing loss does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating hearing loss, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating hearing loss will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4171993